Chronic myeloid leukemia, version 2.2021

Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Lori Maness, Monica Mead, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Kiran Naqvi, Vivian Oehler, Arnel M. Pallera, Mrinal Patnaik, Keith Pratz, Iskra PusicMichal G. Rose, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory, Hema Sundar

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.

Original languageEnglish (US)
Pages (from-to)1385-1415
Number of pages31
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume18
Issue number10
DOIs
StatePublished - Oct 2020

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Chronic myeloid leukemia, version 2.2021'. Together they form a unique fingerprint.

Cite this